Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL11658868 | 0.91 | L3MBTL1 (0.56) | L3MBTL1GAAMAPTLMNAALOX15 | |
| SCHEMBL12909782 | 0.86 | L3MBTL1 (0.68) | L3MBTL1GAAMAPTLMNAMAOB | |
| SCHEMBL339492 | 0.85 | ALOX15 (0.81) | MAPTLMNAALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL5321036 | 0.85 | ALOX15 (0.57) | MAPTALOX15SMN1; SMN2ALDH1A1FFAR1 | |
| SCHEMBL13889134 | 0.85 | ALOX15 (0.57) | MAPTALOX15SMN1; SMN2ALDH1A1FFAR1 | |
| SCHEMBL7463253 | 0.84 | MAPT (0.68) | L3MBTL1GAAMAPTLMNARAB9A | |
| SCHEMBL5827387 | 0.83 | ALOX15 (0.65) | MAPTALOX15SMN1; SMN2ALDH1A1FFAR1 | |
| SCHEMBL29051537 | 0.83 | ALOX15 (0.65) | MAPTALOX15SMN1; SMN2ALDH1A1FFAR1 | |
| SCHEMBL341847 | 0.83 | ALOX15 (0.65) | MAPTALOX15SMN1; SMN2ALDH1A1FFAR1 | |
| SCHEMBL16035699 | 0.83 | ALOX15 (0.65) | GAAMAPTALOX15SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-9182385-B2 | Methods for diagnosis, prognosis and methods of treatment | NODALITY, INC. (US) | 2015-11-10 | — | — | US | claimed |
| US-8778620-B2 | Methods for diagnosis, prognosis and methods of treatment | NODALITY, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130130279-A1 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT | NODALITY, INC. (US) | 2013-05-23 | — | — | US | claimed |
| US-20120309029-A1 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT | NODALITY, INC. (US) | 2012-12-06 | — | — | US | claimed |
| US-8227202-B2 | Methods for diagnosis, prognosis and methods of treatment | NODALITY, INC. (US) | 2012-07-24 | — | — | US | claimed |
| WO-2007059066-A2 | REDUCED SWEETNESS CONFECTIONARY COMPOSITIONS AND COATED/FILLED FOOD PRODUCTS | GENERAL MILLS, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| US-20070110844-A1 | REDUCED SWEETNESS CONFECTIONARY COMPOSITIONS AND COATED/FILLED FOOD PRODUCTS | GENERAL MILLS, INC. | 2007-05-17 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| EP-0159864-B1 | METHOD OF MODIFYING TASTE | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1989-07-19 | — | — | EP | claimed |
| EP-0159864-A2 | Method of modifying taste | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1985-10-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | L3MBTL1 1390/4885GAA 360/4885MAPT 2153/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | L3MBTL1 1390/4885GAA 360/4885MAPT 2153/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | L3MBTL1 598/4885GAA 1358/4885MAPT 4074/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | L3MBTL1 4695/4885GAA 958/4885MAPT 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.